Akoya Biosciences - designated The Spatial Biology Company - is structured to offer end-to-end solutions for high-parameter tissue analysis from discovery through clinical and translational research. These capablites are enabling the development of more precise therapies for immuno-oncology and other drug development applications. Anchored in work undertakan at Stanford by one of the firm's Founders - Dr Gary Nolan - The company has two industry-leading platforms that empower investigators and researchers to gain a deeper understanding of complex diseases such as cancer, and autoimmune or neurological disorders. The CODEX® system is the only benchtop platform that can efficiently quantify more than 40 biomarkers and is ideally suited for biomarker discovery. The Phenoptics platform is the only end-to-end multiplexed immunofluorescence solution with the robustness and high throughput necessary for translational research and clinical trials. In late 2018 it was announced that Akoya Biosciences Acquires Phenoptics Portfolio from PerkinElmer. PerkinElmer has grown its Phenoptics business, to be an industry leader in multiplex immunofluorescence. This acquisition establishes Akoya as a leading provider of quantitative tissue biomarker evaluation, from discovery through translational and clinical research.
